← Back to patent-cliff list
Vorbipiprant sodium
Tier C — Watch / tradeVorbipiprant sodium
Rottapharm Biotech Srl
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PTGER4
Indications (approved)：Colorectal cancer, Solid tumour, Gastric cancer, Rheumatoid arthritis
Regional status
US
-
EU
Phase II
2017-10-05
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vorbipiprant sodium?
Approved indications include: Colorectal cancer, Solid tumour, Gastric cancer, Rheumatoid arthritis.
When does the Vorbipiprant sodium patent expire?
No public expiry year is available for Vorbipiprant sodium yet; this page updates once verified.
How do I get a quote for Vorbipiprant sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09